Drug Search Results
More Filters [+]

Brigatinib

Alternative Names: brigatinib, alunbrig
Latest Update: 2024-12-14
Latest Update Note: Clinical Trial Update

Product Description

Brigatinib is used to treat a certain type of non-small cell lung cancer (NSCLC) that has spread to other parts of the bodys. Brigatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. (Sourced from: https://medlineplus.gov/druginfo/meds/a617016.html)

Mechanisms of Action: ALK Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Indonesia | Ireland | Israel | Italy | Japan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | Norway | Peru | Philippines | Poland | Portugal | Romania | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States

Approved Indications: Lymphoma | Lung Cancer | Non-Small-Cell Lung Cancer | Oncology Solid Tumor Unspecified | Small Cell Lung Cancer | Oncology Unspecified

Known Adverse Events: Headache | Diarrhea

Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Brigatinib

Countries in Clinic: Argentina, Austria, Canada, Chile, China, Croatia, France, Germany, Greece, Hong Kong, Italy, Japan, Korea, Mexico, Netherlands, Romania, Russia, Spain, Sweden, Taiwan, Thailand, United States

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Non-Small-Cell Lung Cancer|Small Cell Lung Cancer

Phase 2: Granuloma|Large-Cell Anaplastic Lymphoma|Lymphoma

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

BrigaPED

P2

Active, not recruiting

Lymphoma

2031-06-30

Briga-PED

P2

Recruiting

Large-Cell Anaplastic Lymphoma|Granuloma

2029-12-01

ABP-2019

P2

Unknown Status

Small Cell Lung Cancer|Non-Small-Cell Lung Cancer

2026-01-16

NCT04318938

P2

Active, not recruiting

Small Cell Lung Cancer|Non-Small-Cell Lung Cancer

2026-01-16

Recent News Events